Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/03/21
Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of ObesityGlobeNewsWire • 08/03/21
Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl SyndromeGlobeNewsWire • 07/28/21
Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021GlobeNewsWire • 07/27/21
Rhythm Pharma's Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic MutationsBenzinga • 07/23/21
Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR DeficiencyGlobeNewsWire • 07/23/21
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR DeficiencyGlobeNewsWire • 05/21/21
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass EstimatesZacks Investment Research • 05/03/21
Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/21
Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021GlobeNewsWire • 03/20/21
Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021GlobeNewsWire • 03/09/21
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 03/01/21
Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/10/21
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström SyndromesGlobeNewsWire • 12/22/20
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR DeficiencyGlobeNewsWire • 11/27/20
Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020GlobeNewsWire • 11/04/20
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & EndocrinologyGlobeNewsWire • 10/30/20